<div id="readability-page-1">Seaport Therapeutics (SPTX) on Monday filed for an initial public offering of 11.8M shares priced between $16 and $18 each, seeking to raise as much as about $212M. At $18 per share, the clinical-stage biotech firm will have a market value of $912M. The company has applied to list its shares on the Nasdaq Global Market under the ticker SPTX. Goldma...</div>

PRTC

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

PRTCY

<p>Seaport Therapeutics (SPTX) 已提交首次公开募股（IPO）申请，计划通过发行 1180 万股，价格在每股 16 至 18 美元之间，筹集最多 2.12 亿美元。该公司专注于开发用于神经精神疾病的口服疗法，目标是在最高股价时实现 9.12 亿美元的市场价值。高盛、摩根大通和 Leerink Partners 负责此次发行。Seaport 去年报告净亏损 7490 万美元，并获得了 PureTech Health 的支持，后者持有该公司近 50% 的股份</p>

Drug developer Seaport Therapeutics seeks up to $212M in US IPO

PureTech Health

PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS

纳斯达克 OMX 交易所

高盛

GS Hldg R

药物开发商 Seaport Therapeutics 计划通过美国 IPO 筹集最多 2.12 亿美元